Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck &
Co. Inc., and Eli Lilly and Company
NEW YORK, January 16, 2013
NEW YORK, January 16, 2013 /PRNewswire/ --
PremierEquityReports.com provides investors with quality research and analysis
on U.S. equities on the move and today issues a report on the top
pharmaceutical companies for 2013: Crown Marketing Inc. (OTCBB: CWNM), Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), and Eli Lilly and Company
Crown Marketing Inc. (OTCBB: CWNM) has recently patented a controlled drug
delivery technology that aims not only to improve the safety and
pharmacokinetics of controlled-release medication, but also to streamline the
manufacturing process for existing facilities without significantly increasing
costs. Crown Marketing is seeking to change the time-release process entirely,
providing a true 24-hour sustained-release delivery system.
Crown Marketing has also announced that the smart drug delivery revolution has
Read the entire press release issued by Crown Marketing Inc. (OTCBB: CWNM)
Pfizer Inc. (NYSE: PFE) has been the buzz of Wall Street with rumors
circulating that the company will split its drug division in two. President
Geno Germano said, "…probably going to evolve to two, where there's the
innovative business and the value business," in a January 8 ^th interview.
This news excites analysts because a split would make sense and would turn
eyes away from its pipeline and base business to financial engineering.
TheStreet.com, website of infamous stock picker Jim Cramer, has reiterated a
buy rating on Pfizer with a rating score of A-.
Read the entire press release issued by TheStreet.com about Pfizer Inc. (NYSE:
Merck & Co. Inc. (NYSE: MRK) recently announced that it is taking its
cholesterol management drug, Tredaptive, off the market. The decision was
based on preliminary data from a long term safety study.
Read the entire press release about Merck & Co. Inc. (NYSE: MRK) here:
Sam Isaly's Orbimed Advisors, a large health care fund investing in healthcare
companies, reported a position of 4.6 million shares in Merck, a 33% increase
from three months earlier.
Eli Lilly and Company's (NYSE: LLY) brain-plaque diagnostic was approved for
use in adult patients by European health regulators on Tuesday. Their imaging
agent is used to detect brain plaques that are considered a possible cause of
Alzheimer's disease. This radioactive diagnostic called Amyvid, was approved
for use in the United States last April. The brain plaques were previously
only detectable through autopsy.
Read the entire press release about Eli Lilly and Company (NYSE: LLY) here:
Sign up to receive detailed reports and stock picks at
http://www.PremierEquityReports.com . For real-time trade updates, follow our
award winning hedge fund trader on Twitter @StockBrainiac. Premier Equity
Reports also offers a FREE text message alert service to ensure that you
receive all alerts. Simply text " reports " to 63566 .
Premier Equity Reports is the U.S. leader in equity reports, offering quality
reports to investors looking for the most undervalued companies in the market.
Premier Equity Reports provides its subscribers with timely information and
exclusive analysis on U.S. companies with substantial upside potential.
Premier Equity Reports is the #1 free financial newsletter in the industry.
Sign up now and see why thousands have joined already.
Disclosure: PremierEquityReports.com is not a registered investment advisor
and nothing contained in any materials should be construed as a recommendation
to buy or sell securities. Investors should always conduct their own due
diligence with any potential investment. Premier Equity Reports is a wholly
owned entity of Equities Awareness Group LLC. Equities Awareness Group LLC has
been compensated one hundred thousand dollars for marketing awareness on Crown
Marketing Inc. Please read our report and visit our website, for complete
risks and disclosures.
Contact Information: Equities Awareness Group LLCMichael Perinotti
email@example.com http://www.EquitiesAG.com +1-201-917-5934 Third Party
Publishing Provider: FNNewswire, a FN Media Group, LLC Company.
Press spacebar to pause and continue. Press esc to stop.